Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study.
Kokaliaris C, Garba A, Matuska M, Bronzan RN, Colley DG, Dorkenoo AM, Ekpo UF, Fleming FM, French MD, Kabore A, Mbonigaba JB, Midzi N, Mwinzi PNM, N'Goran EK, Polo MR, Sacko M, Tchuem Tchuenté LA, Tukahebwa EM, Uvon PA, Yang G, Wiesner L, Zhang Y, Utzinger J, Vounatsou P. Kokaliaris C, et al. Among authors: wiesner l. Lancet Infect Dis. 2022 Jan;22(1):136-149. doi: 10.1016/S1473-3099(21)00090-6. Epub 2021 Dec 2. Lancet Infect Dis. 2022. PMID: 34863336 Free PMC article.
Comparison of Permitted Daily Exposure (PDE) Values for Active Pharmaceutical Ingredients (APIs) - Evidence of Robust Approach.
Sehner C, Bernier T, Blum K, Clemann N, Glogovac M, Hawkins WA, Kohan M, Linker F, Lovsin-Barle E, Osadolor O, Pfister T, Schulze E, Schwind M, Tuschl G, Wiesner L. Sehner C, et al. Among authors: wiesner l. Regul Toxicol Pharmacol. 2024 May 21:105649. doi: 10.1016/j.yrtph.2024.105649. Online ahead of print. Regul Toxicol Pharmacol. 2024. PMID: 38782234
Validation and application of an online extraction and liquid chromatography tandem mass spectrometry assay for the analysis of delamanid and its DM-6705 metabolite in human breast milk.
Mkhize B, Court R, Castel S, Joubert A, van der Merwe M, Maartens G, Conradie F, Wiesner L. Mkhize B, et al. Among authors: wiesner l. J Pharm Biomed Anal. 2024 May 16;246:116225. doi: 10.1016/j.jpba.2024.116225. Online ahead of print. J Pharm Biomed Anal. 2024. PMID: 38761519
A study protocol to characterise pathophysiological and molecular markers of rheumatic heart disease and degenerative aortic stenosis using multiparametric cardiovascular imaging and multiomics techniques.
Mutithu DW, Aremu OO, Mokaila D, Bana T, Familusi M, Taylor L, Martin LJ, Heathfield LJ, Kirwan JA, Wiesner L, Adeola HA, Lumngwena EN, Manganyi R, Skatulla S, Naidoo R, Ntusi NAB. Mutithu DW, et al. Among authors: wiesner l. PLoS One. 2024 May 13;19(5):e0303496. doi: 10.1371/journal.pone.0303496. eCollection 2024. PLoS One. 2024. PMID: 38739622 Free PMC article.
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
Gausi K, Ignatius EH, De Jager V, Upton C, Kim S, McKhann A, Moran L, Wiesner L, von Groote-Bidlingmaier F, Marzinek P, Vanker N, Yvetot J, Pierre S, Rosenkranz SL, Swindells S, Diacon AH, Nuermberger EL, Denti P, Dooley KE; A5312 Study Team. Gausi K, et al. Among authors: wiesner l. Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38564365
Molecular docking, molecular dynamics simulations and binding free energy studies of interactions between Mycobacterium tuberculosis Pks13, PknG and bioactive constituents of extremophilic bacteria.
Nyambo K, Tapfuma KI, Adu-Amankwaah F, Julius L, Baatjies L, Niang IS, Smith L, Govender KK, Ngxande M, Watson DJ, Wiesner L, Mavumengwana V. Nyambo K, et al. Among authors: wiesner l. Sci Rep. 2024 Mar 21;14(1):6794. doi: 10.1038/s41598-024-57124-9. Sci Rep. 2024. PMID: 38514663 Free PMC article.
Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
van Heerden JK, Meintjes G, Barr D, Zhao Y, Griesel R, Keene CM, Wiesner L, Galileya LT, Denti P, Maartens G. van Heerden JK, et al. Among authors: wiesner l. J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):260-267. doi: 10.1097/QAI.0000000000003341. J Acquir Immune Defic Syndr. 2024. PMID: 38408216 Free PMC article.
307 results